Cargando…

Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma

Background: Endobiliary radiofrequency ablation (RFA) is a promising treatment modality for patients with extrahepatic cholangiocarcinoma (eCCA). However, no study has investigated the combined use of endobiliary RFA and gemcitabine plus cisplatin (GC) chemotherapy. This study aimed to examine the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Tadahisa, Naitoh, Itaru, Kitano, Rena, Ibusuki, Mayu, Kobayashi, Yuji, Sumida, Yoshio, Nakade, Yukiomi, Ito, Kiyoaki, Yoneda, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029596/
https://www.ncbi.nlm.nih.gov/pubmed/35448156
http://dx.doi.org/10.3390/curroncol29040182
_version_ 1784691917967065088
author Inoue, Tadahisa
Naitoh, Itaru
Kitano, Rena
Ibusuki, Mayu
Kobayashi, Yuji
Sumida, Yoshio
Nakade, Yukiomi
Ito, Kiyoaki
Yoneda, Masashi
author_facet Inoue, Tadahisa
Naitoh, Itaru
Kitano, Rena
Ibusuki, Mayu
Kobayashi, Yuji
Sumida, Yoshio
Nakade, Yukiomi
Ito, Kiyoaki
Yoneda, Masashi
author_sort Inoue, Tadahisa
collection PubMed
description Background: Endobiliary radiofrequency ablation (RFA) is a promising treatment modality for patients with extrahepatic cholangiocarcinoma (eCCA). However, no study has investigated the combined use of endobiliary RFA and gemcitabine plus cisplatin (GC) chemotherapy. This study aimed to examine the feasibility and efficacy of endobiliary RFA with GC therapy for patients with unresectable eCCA. Methods: The study outcomes included overall survival (OS), progression-free survival (PFS), time to recurrent biliary obstruction (RBO), and adverse events associated with the treatment. These parameters were retrospectively compared between 25 patients who underwent RFA with self-expandable metal stent (SEMS) placement followed by GC therapy (with-RFA group) and a control cohort of 25 patients who underwent SEMS placement alone and GC therapy (without-RFA group). Results: The median time to RBO was significantly longer in the with-RFA group (10.7 versus 5.2 months, p = 0.048). The median OS was significantly higher in patients with locally advanced tumors in the with-RFA group (23.1 versus 16.6 months, p = 0.032), but did not differ significantly in patients with metastasis (11.4 versus 8.5 months, p = 0.180). Similarly, the median PFS was significantly higher in the with-RFA group in patients with locally advanced disease (10.1 versus 7.3 months, p = 0.015), while there was no significant difference in patients with metastasis (5.4 versus 4.4 months, p = 0.529). The rates of various toxicities did not differ significantly between the groups. Conclusions: Endobiliary RFA prolonged the patency period of uncovered SEMS combined with GC therapy in patients with eCCA. Although RFA also yielded survival benefits, its effect was restricted to locally advanced tumors.
format Online
Article
Text
id pubmed-9029596
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90295962022-04-23 Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma Inoue, Tadahisa Naitoh, Itaru Kitano, Rena Ibusuki, Mayu Kobayashi, Yuji Sumida, Yoshio Nakade, Yukiomi Ito, Kiyoaki Yoneda, Masashi Curr Oncol Article Background: Endobiliary radiofrequency ablation (RFA) is a promising treatment modality for patients with extrahepatic cholangiocarcinoma (eCCA). However, no study has investigated the combined use of endobiliary RFA and gemcitabine plus cisplatin (GC) chemotherapy. This study aimed to examine the feasibility and efficacy of endobiliary RFA with GC therapy for patients with unresectable eCCA. Methods: The study outcomes included overall survival (OS), progression-free survival (PFS), time to recurrent biliary obstruction (RBO), and adverse events associated with the treatment. These parameters were retrospectively compared between 25 patients who underwent RFA with self-expandable metal stent (SEMS) placement followed by GC therapy (with-RFA group) and a control cohort of 25 patients who underwent SEMS placement alone and GC therapy (without-RFA group). Results: The median time to RBO was significantly longer in the with-RFA group (10.7 versus 5.2 months, p = 0.048). The median OS was significantly higher in patients with locally advanced tumors in the with-RFA group (23.1 versus 16.6 months, p = 0.032), but did not differ significantly in patients with metastasis (11.4 versus 8.5 months, p = 0.180). Similarly, the median PFS was significantly higher in the with-RFA group in patients with locally advanced disease (10.1 versus 7.3 months, p = 0.015), while there was no significant difference in patients with metastasis (5.4 versus 4.4 months, p = 0.529). The rates of various toxicities did not differ significantly between the groups. Conclusions: Endobiliary RFA prolonged the patency period of uncovered SEMS combined with GC therapy in patients with eCCA. Although RFA also yielded survival benefits, its effect was restricted to locally advanced tumors. MDPI 2022-03-23 /pmc/articles/PMC9029596/ /pubmed/35448156 http://dx.doi.org/10.3390/curroncol29040182 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Inoue, Tadahisa
Naitoh, Itaru
Kitano, Rena
Ibusuki, Mayu
Kobayashi, Yuji
Sumida, Yoshio
Nakade, Yukiomi
Ito, Kiyoaki
Yoneda, Masashi
Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
title Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
title_full Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
title_fullStr Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
title_full_unstemmed Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
title_short Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
title_sort endobiliary radiofrequency ablation combined with gemcitabine and cisplatin in patients with unresectable extrahepatic cholangiocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029596/
https://www.ncbi.nlm.nih.gov/pubmed/35448156
http://dx.doi.org/10.3390/curroncol29040182
work_keys_str_mv AT inouetadahisa endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT naitohitaru endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT kitanorena endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT ibusukimayu endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT kobayashiyuji endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT sumidayoshio endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT nakadeyukiomi endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT itokiyoaki endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma
AT yonedamasashi endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma